Literature DB >> 10619944

Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder.

A D Watters1, S A Ballantyne, J J Going, K M Grigor, J M Bartlett.   

Abstract

OBJECTIVE: To determine if changes in chromosome 7 and 17 copy number can be used to predict recurrence in patients with primary noninvasive (pTa) or superficially invasive (pT1) transitional cell carcinoma (TCC) of the urinary bladder. PATIENTS AND METHODS: Tissue specimens for 129 tumours from 52 patients (38 men and 14 women) with pTa/pT1 TCC at first diagnosis were retrieved from pathology archives. All patient notes were accessed and disease outcome documented for superficial (pTa/pT1) recurrence or progression to detrusor muscle invasion (>/= pT2). The tumours were examined for chromosomal copy number of chromosomes 7 and 17 using fluorescence in situ hybridization (FISH) with chromosome-specific probes. The copy number of chromosomes 7 and 17 was determined in interphase nuclei on intact 6 microm tissue sections.
RESULTS: Aneusomy of chromosomes 7 and 17 was detected in the index primary tumours of 10 of 32 (31%) patients with subsequent recurrent disease. No aneusomy for these chromosomes was detected in primary tumours from 20 patients with no detect-able recurrence (P = 0.0082). The relative risk of recurrence was 3.62 times greater (95% confidence interval 1.6-8.1, Cox's multiple regression P = 0.0019) for patients with chromosomal aneusomy in primary TCC. Neither stage nor grade of the primary tumours was associated with recurrence in these patients, nor was there a significant association with increased grade (G2/3) or stage (>/= pT2) at recurrence.
CONCLUSION: These results suggest that the measurement of aneusomy by FISH, using markers for chromosomes 7 and 17, predict recurrence in a subgroup of patients with pTa/pT1 tumours at presentation. This finding may offer a new objective and quantitative test for patients destined to recur.

Entities:  

Mesh:

Year:  2000        PMID: 10619944     DOI: 10.1046/j.1464-410x.2000.00326.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  Fluorescence in situ hybridization in paraffin tissue sections: pretreatment protocol.

Authors:  A D Watters; J M S Bartlett
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

2.  External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.

Authors:  John M S Bartlett; Merdol Ibrahim; Bharat Jasani; John M Morgan; Ian Ellis; Elaine Kay; Hilary Magee; Sarah Barnett; Keith Miller
Journal:  J Clin Pathol       Date:  2006-09-08       Impact factor: 3.411

3.  Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.

Authors:  J Edwards; P Duncan; J J Going; K M Grigor; A D Watters; J M Bartlett
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

4.  HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder.

Authors:  Z Latif; A D Watters; I Dunn; K M Grigor; M A Underwood; J M S Bartlett
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.